NoCanTher enters clinical study phase

np nocanther clinical study


NoCanTher now enters its final phase with the start of a clinical study aimed at patients with unresectable, locally advanced pancreatic cancer that has not metastasized, who have palliative chemotherapy as the only therapeutic alternative. This population accounts for 20% of patients with pancreatic cancer.

This important milestone marks the culmination of over ten years of scientific work and is one of the last phases of the NoCanTher project. The study will be led from Spain and carried out at two sites - Vall d'Hebron Institute of Oncology (Barcelona) and Hospital Universitario de Fuenlabrada (Madrid). 


Read the institutional press releases from Vall d'Hebron Institute of Oncology, lead of the study, and from IMDEA Nanociencia, coordinator of the project. 

NoCanTher named as one of the “Made in Madrid” projects by Telemadrid


The Project featured in an article from a regional TV station highlighting the 10 research projects "made in Madrid" that the scientific community is looking towards. The article was published as part of Madrid Science Week an initiative by the regional government to promote science and innovation.

Regional Government visit IMDEA Nanociencia - visitors introduced to the NoCanTher Project


As part of Madrid Science week, the Regional Government celebrated their government council meeting at the IMDEA Nanocienica institute. As part of the visit they were shown around the laboratories and had the chance to find out about the various EU funded projects coordinated at the Institute. Prof A. Somoza (co-coordinator of the NoCanTher project) had the chance to give the Ministers a tour of the NoCanTher laboratories where they were able to see first-hand the work that is going on in the project.

2020.11.11 visita consejo gobierno cm

The Consortium continues working from home


2020.04.21 onlinemeeting

The Consortium of NoCanTher has gathered in an online meeting to discuss publications and future dissemination plans. In spite of the COVID-19 situation, the work keeps going on. 

More Articles ...